Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.57
+0.08000.76%
Pre-market: 10.570.00000.00%07:03 EDT
Volume:1.58M
Turnover:16.61M
Market Cap:2.31B
PE:-7.48
High:10.66
Open:10.42
Low:10.32
Close:10.49
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:1.02
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.45
PE(LYR):-7.44

Loading ...

Ocular Therapeutix Joins Baird Global Healthcare Conference Fireside Chat

Reuters
·
Yesterday

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

GlobeNewswire
·
Yesterday

Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds

Simply Wall St.
·
Aug 25

Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset

TIPRANKS
·
Aug 17

Ocular Therapeutix rises 10.4%

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Shares up 12.7% Premarket After Rival EyePoint's Eye Drug Misses Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Grants New SVP Beth Rada Options for 85,000 Shares, 28,000 RSUs Under Inducement Plan

Reuters
·
Aug 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Tarsus Pharmaceuticals Q2 Sales Beat Estimates, Lifts 2026 Xdemvy Sales Outlook

Reuters
·
Aug 06

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Reuters
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Canada's Kits Eyecare Q2 Revenue Slightly Beats on Glasses Segment Growth

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

MT Newswires Live
·
Aug 04

Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 04